Use Case: Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott’s 4th Generation ARCHITECT HIV Antigen/Antibody Combo Test

In response to the growing need to demonstrate how medical technologies fit into the emerging value-based paradigm for providers, payers, and patients, AdvaMed launched a Strategic Value Initiative to develop an approach to value assessment for medical technologies that can be used by Medical technology companies as well as by health systems, payers, and other stakeholders.

This use case demonstrates the value of Abbott’s 4th generation ARCHITECT HIV Antigen/Antibody combo (ARCHITECT HIV Ag/Ab Combo) test across all of the identified value drivers and for a range of stakeholders. The test works by simultaneously detecting HIV p24 antigen and antibodies to both HIV Type 1 and/or HIV Type 2 in human serum and plasma. It is intended for use as an aid in diagnosis of HIV-1/HIV-2, including acute/primary HIV-1 infection, in subjects age two and up and in pregnant women.